Acumen Pharmaceuticals, Inc.

10/20/2025

At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members and the amazing work they do!

October's 'Ask Acumen' featured team member is Todd Feaster, PsyD, Senior Clinical Research Scientist.

🔗 Click the link below to get a behind-the-scenes look at Todd's journey, passions, and outstanding contributions to our mission: https://acumenpharm.com/ask-acumen/

10/16/2025

We’re pleased to share this piece from Pharmaceutical-Technology on the rise of new U.S. biotech hubs and what they mean for the future of innovation. The article features insights from our CEO, Daniel O'Connell.

At Acumen, we know that being close to research centers, infrastructure, and scientific communities brings us closer to new possibilities for patients and families affected by Alzheimer's.

Check out the article here:

While established US biotech hubs may still rule the roost, emerging competitors are looking to grab a larger slice of the market.

10/14/2025

Last week, Acumen’s Senior Vice President of Clinical Development, Laura Rosen, MD, PhD, joined an expert panel at the 3rd Annual Fluid & Imaging Biomarkers in Neuroscience Summit in Boston.

The discussion, “P-tau217: Clinical Promise, Regulatory Hurdles & the Path to Surrogate Endpoint Status,” brought together leaders in Alzheimer’s research to explore how p-tau217 is shaping the future of diagnostics and clinical trials. We’re proud to see Acumen’s voice represented in conversations that advance the science and bring us closer to more scalable and accessible Alzheimer’s diagnostics.

10/10/2025

Today on , we’re reminded that caring for brain health includes caring for mental health. At Acumen, we believe every moment matters—for patients, families, and each other—and we stand with the global community to raise awareness, reduce stigma, and move science forward with compassion.

10/09/2025

We’re proud to share that our team has published recruitment insights from the Phase 1 INTERCEPT-AD trial of sabirnetug (ACU193) in the journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions.

The manuscript, “Recruitment and eligibility in a Phase 1 early Alzheimer’s disease trial of sabirnetug,” highlights important learnings about site recruitment strategies and eligibility rates.

Read the publication here: https://doi.org/10.1002/trc2.70161

10/01/2025

👣This past weekend Acumen team members hit the pavement for the Alzheimer's Association's 'Walk to End Alzheimer's' in the Twin Cities. Kudos to Robyn Moxon for her commitment to the cause!

09/29/2025

Today is National Coffee Day! So many important moments happen over a coffee break: conversations, connections, ideas, reminders of what really matters.

Here’s to holding on to those moments, and to making every one count.

09/22/2025

Yesterday, on World Alzheimer’s Day, Acumen team members Katie Rink, Maddelyn Hyland, and Amy Hutchinson, along with their families & friends, joined hundreds of others in North Shore, IL and Bloomington, IN for the Alzheimer's Association 'Walk to End Alzheimer’s'. Walking alongside so many who are impacted by this disease was a powerful reminder of why we do what we do, kudos to all who participated!

09/16/2025

At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members and the amazing work they do!

September's 'Ask Acumen' featured team member is Katie Rink, SPHR, SHRM-CP, Senior Director, Human Resources.

🔗 Click the link below to get a behind-the-scenes look at Katie's journey, passions, and outstanding contributions to our mission: https://acumenpharm.com/ask-acumen/

09/12/2025

We're proud to see our team member Mahsan Rafizadeh representing Acumen at the 2025 'Walk to End Alzheimer's Kickoff Event' in Oahu this week.

The event is a great opportunity for those who participate in the Walk and support the cause to gather, share energy, and spread awareness.

09/11/2025

Acumen CEO Daniel O'Connell joined Brandon Li with 'Power to the Patients' Podcast to share how we’re reshaping the future of Alzheimer’s treatment – and why rebuilding patient trust is essential to that mission.

From our work developing sabirnetug to the importance of transparency and empathy in clinical development, Dan shares what meaningful progress looks like in Alzheimer’s research.

You can listen to the full interview at: https://youtu.be/FHJqtoPF9Qg?si=RGobqyRHNzCnnKxK

With over 25 years of experience building and investing in CNS companies, Daniel shares the story of why he placed a big bet on Acumen — from its origins as ...

09/09/2025

Acumen participated in a fireside chat last week at the Cantor Fitzgerald Global Healthcare Conference in New York, where we shared updates on sabirnetug’s progress, our unique mechanism of action, and our future development plans.

Check out the webcast here: https://investors.acumenpharm.com/events/event-details/cantor-global-healthcare-conference-2025